Congenital adrenal hyperplasia is a disorder of decreased cortisol production coupled with an increase in androgens from a compensatory adrenocorticotropic hormone drive.
Three-week-old baby referred to the paediatric endocrine clinic from a general paediatrician with ambiguous genitalia, accompanied by very anxious and upset parents.
Giving hydrocortisone four times daily at a time-varying dose may be the best approach for children with congenital adrenal hyperplasia, say the authors of a pharmaco-kinetic and pharmaco-dynamic modelling study.
Factors including age at diagnosis and the specific disease influence the likelihood of children with chronic endocrine conditions being lost to follow-up, show French study findings.
Our podcast with Dr Sogol Mostoufi, from the Children’s Hospital of Philadelphia in Pennsylvania, USA, focuses on the treatment-related endocrine side effects commonly experienced by childhood cancer survivors, and the need for screening, life-long follow-up and treatment in this high-risk population.
The European Cooperation in Science and Technology Action DSDnet group have published recommendations for standardised data collection during clinical follow-up of patients with differences of sexual development.
Plasma concentrations of the adrenal-derived 11-oxygenated-C19 androgen 11-ketotestosterone strongly correlate with salivary levels in children with congenital adrenal hyperplasia, UK researchers report.
The risk of a false–positive result on a low-dose adrenocorticotropic hormone stimulation test can be reduced in children by measuring cortisol levels at three consecutive time points instead of just one, researchers say.
Researchers have defined urinary steroid metabolite levels that indicate inadequate and excessive adrenal suppression for children with congenital adrenal hyperplasia undergoing glucocorticoid treatment.
In our first edition, Professor Frederic Castinetti discussing the results of an international collaboration to study the natural history and treatment outcomes of multiple endocrine neoplasia type 2B, and Professor Martin Savage comments on a randomized trial of letrozole versus testosterone in boys with constitutional delay of growth and puberty.
